Exciting advances in biosciences and bioengineering have taken place over the last two decades resulting in an explosion in the number of companies that translate these advances into products for human health care. Currently, there are over 1,200 biotechnology companies in the Unites States alone and annual sales of biotechnology-derived pharmaceuticals and diagnostics is estimated to exceed $10 billion dollars worldwide. Clearly, the birth of an entire industry poses opportunities and challenges in education. The future leaders in the field of 'pharmaceutical biotechnology' demands that we make concomitant innovations in the training of the next generation of scientists and engineers.
In order to address these challenges, the College of Engineering and Applied Science and the School of Pharmacy joined together to establish the Center for Pharmaceutical Biotechnology (CPB). The vision is to partner with pharmaceutical biotechnology companies to form a unique program emphasizing multi-disciplinary scientific education as well as training in non-scientific disciplines critical to the success of this industry: regulatory affairs, health care policy, technology transfer, finance, and marketing. Final approval for the CPB was received in January 1997 when Dr. John Buechner, president of the University of Colorado, sanctioned the enterprise. The CPB was the first center to bridge the University of Colorado Anschutz Medical Campus and the main campus in Boulder. The CPB originated from a collaborative relationship between the PhD programs in pharmaceutical sciences and chemical engineering.